Baclofen reduces binge eating in a double-blind, placebo-controlled, crossover study

Behavioural Pharmacology

Volumn 23, Issue 5-6, 2012, Pages 616-625

  Corwin, Rebecca L ^a   Boan, Jarol ^b,c   Peters, Kathryn F ^c   Ulbrecht, Jan S ^a,b,c  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c Penn State Institute for Diabetes and Obesity (PSIDO)   (United States)

Author keywords

Baclofen; binge eating; bulimia nervosa; c aminobutyric acid B; human

Indexed keywords

BACLOFEN; PLACEBO;

ADULT; ARTICLE; BINGE EATING DISORDER; BINGE EATING SCALE; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG TOLERANCE; FATIGUE; FEMALE; FOOD CRAVING INVENTORY II; GASTROINTESTINAL SYMPTOM; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; INFORMATION PROCESSING; LOW DRUG DOSE; MALE; NAUSEA; OUTCOME ASSESSMENT; PSYCHOLOGIC TEST; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; WITHDRAWAL SYNDROME;

ADULT; ANXIETY; BACLOFEN; BINGE-EATING DISORDER; CROSS-OVER STUDIES; DEPRESSION; DOUBLE-BLIND METHOD; DRUG MONITORING; FATIGUE; FEEDING BEHAVIOR; FEMALE; GABA-B RECEPTOR AGONISTS; HUMANS; MALE; MIDDLE AGED; PLACEBO EFFECT; PSYCHIATRIC STATUS RATING SCALES; SELF REPORT; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84864876778     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0b013e328357bd62     Document Type: Article

References (48)

1. Allen S, Dalton WT (2011). Treatment of eating disorders in primary care: a systematic review. J Health Psychol 16:1165-1176.
2. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (DSM-IV-TR). Washington: American Psychiatric Association.
3. Arima H, Oiso Y (2010). Positive effect of baclofen on body weight reduction in obese subjects: a pilot study. Intern Med 49:2043-2047.
4. Assadi SM, Radgoodarzi R, Ahmadi-Abhari SA (2003). Baclofen for maintenance treatment of opioid dependence: a randomized double-blind placebo-controlled clinical trial [ISRCTN32121581]. BMC Psychiatry 3:16.
5. Beck AT, Steer RA (1993). Manual for the Beck Depression Inventory. San Antonio, TX: Psychological Corporation.
6. Bello NT, Hajnal A (2010). Dopamine and binge eating behaviors. Pharmacol Biochem Behav 97:25-33.
7. Berner LA, Bocarsly ME, Hoebel BG, Avena NM (2009). Baclofen suppresses binge eating of pure fat but not a sugar-rich or sweet-fat diet. Behav Pharmacol 20:631-634.
8. Boan J, Kolotkin R, Westman E, Grant J (2004). Binge eating, exercise patterns and quality of life improve after Roux-en-Y Gastric Bypass (RYGB) for morbid obesity. Obes Surg 14:341-348.
9. Brebner K, Childress AR, Roberts DC (2002). A potential role for GABA(B) agonists in the treatment of psychostimulant addiction. Alcohol Alcohol 37:478-484.
10. Broft AI, Spanos A, Corwin R, Mayer L, Steinglass J, Devlin MJ, et al. (2007). Baclofen as a novel treatment for binge eating: an open-label pilot study. Int J Eat Disord 40:687-691.
11. Brvar M, Vrtovec M, Kovac D, Kozelj G, Pezdir T, Bunc M (2007). Haemodialysis clearance of baclofen. Eur J Clin Pharmacol 63:1143-1146.
12. Buda-Levin A, Wojnicki FHE, Corwin RL (2005). Baclofen reduces fat intake under binge-type conditions. Physiol Behav 86:176-184.
13. Corwin RL, Babbs RK (2012). Rodent models of binge eating: are they models of addiction? ILAR J (In press).
14. Corwin RL, Wojnicki FHE (2009). Baclofen, raclopride, and naltrexone differentially affect intake of fat and sucrose under limited access conditions. Behav Pharmacol 20:537-548.
15. Corwin RL, Avena NM, Boggiano MM (2011). Feeding and reward: perspectives from three rat models of binge eating. Physiol Behav 104:87-97.
16. Crowley N, Budak A, Byrne TK, Thomas S (2011). Patients who endorse more binge eating triggers before gastric bypass lose less weight at 6 months. Surg Obes Relat Dis 7:55-59.
17. Czyzyk TA, Sahr AE, Statnick MA (2010). A model of binge-like eating behavior in mice that does not require food deprivation or stress. Obesity (Silver Spring) 18:1710-1717.
18. Edwards S, Kenna GA, Swift RM, Leggio L (2011). Current and promising pharmacotherapies, and novel research target areas in the treatment of alcohol dependence: a review. Curr Pharm Des 17:1323-1332.
19. Engelberg MJ, Gauvin L, Steiger H (2005). A naturalistic evaluation of the relation between dietary restraint, the urge to binge, and actual binge eating: a clarification. Int J Eat Disord 38:355-360.
20. Erhardt S, Mathé JM, Chergui K, Engberg G, Svensson TH (2002). GABA(B) receptor-mediated modulation of the firing pattern of ventral tegmental area dopamine neurons in vivo. Naunyn Schmiedebergs Arch Pharmacol 365: 173-180.
21. Fahey TD, Insel PM, Roth WT (2005). Fit and Well. 6th ed. Columbus Ohio: McGraw-Hill Co.
22. Franklin TR, Harper D, Kampman K, Kildea-McCrea S, Jens W, Lynch KG, et al. (2009). The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study. Drug Alcohol Depend 103:30-36.
23. Franklin TR, Wang Z, Sciortino N, Harper D, Li Y, Hakun J, et al. (2011). Modulation of resting brain cerebral blood flow by the GABA B agonist, baclofen: a longitudinal perfusion fMRI study. Drug Alcohol Depend 117:176-183.
24. Franklin TR, Shin J, Jagannathan K, Suh JJ, Detre JA, O'Brien CP, Childress AR (2012). Acute baclofen diminishes resting baseline blood flow to limbic structures: a perfusion fMRI study. Drug Alcohol Depend [Epub ahead of print].
25. Gormally J, Black S, Daston S, Rardin D (1982). The assessment of binge eating severity among obese persons. Addict Behav 7:47-55.
26. Herrmann C (1997). International experiences with the Hospital Anxiety and Depression Scale-a review of validation data and clinical results. J Psychosom Res 42:17-41.
27. Herzog DB, Franko DL, Dorer DJ, Keel PK, Jackson S, Manzo MP (2006). Drug abuse in women with eating disorders. Int J Eat Disord 39:364-368.
28. Hudson JI, Hiripi E, Pope HG Jr, Kessler RC (2007). The prevalence and correlates of eating disorders in the national comorbidity survey replication. Biol Psychiatry 61:348-358.
29. Kahn R, Biswas K, Childress AR, Shoptaw S, Fudala PJ, Gorgon L, et al. (2009). Multi-center trial of baclofen for abstinence initiation in severe cocainedependent individuals. Drug Alcohol Depend 103:59-64.
30. Karila L, Gorelick D,Weinstein A, Noble F, Benyamina A, Coscas S, et al. (2008). New treatments for cocaine dependence: a focused review. Int J Neuropsychopharmacol 11:425-438.
31. Knutsson E, Lindblom U, Mårtensson A (1974). Plasma and cerebrospinal fluid levels of baclofen (Lioresal) at optimal therapeutic responses in spastic paresis. J Neurol Sci 23:473-484.
32. Livhits M, Mercado C, Yermilov I, Parikh JA, Dutson E, Mehran A, et al. (2010). Behavioral factors associated with successful weight loss after gastric bypass. Am Surg 76:1139-1142.
33. McElroy SL, Guerdjikova AI, Winstanley EL, O'Melia AM, Mori N, Keck PE Jr, Hudson JI (2011). Sodium oxybate in the treatment of binge eating disorder: an open-label, prospective study. Int J Eat Disord 44:262-268.
34. Mitchell JE, de Zwaan M, Roerig JL (2003). Drug therapy for patients with eating disorders. Curr Drug Targets CNS Neurol Disord 2:17-29.
35. Niego SH, Kofman MD, Weiss JJ, Geliebter A (2007). Binge eating in the bariatric surgery population: a review of the literature. Int J Eat Disord 40:349-359.
36. Patel SM, Ebenezer IS (2010). Effects of chronic systemic administration of the GABA(B) receptor agonist baclofen on food intake and body weight in rats. Eur J Pharmacol 635:129-134.
37. Peterson CB, Miller KB, Willer MG, Ziesmer J, Durkin N, Arikian A, Crow SJ (2011). Cognitive-behavioral therapy for subthreshold bulimia nervosa: a case series. Eat Weight Disord 16:e204-e208.
38. Rao RE, Wojnicki FHE, Coupland J, Ghosh S, Corwin RLW (2008). Baclofen, raclopride and naltrexone differentially reduce solid fat emulsion intake under limited access conditions. Pharmacol Biochem Behav 89:581-590.
39. Shellenberger MK, Groves L, Shah J, Novack GD (1999). A controlled pharmacokinetic evaluation of tizanidine and baclofen at steady state. Drug Metab Dispos 27:201-204.
40. Swanson SA, Crow SJ, Le Grange D, Swendsen J, Merikangas KR (2011). Prevalence and correlates of eating disorders in adolescents: results from the national comorbidity survey replication adolescent supplement. Arch Gen Psychiatry 68:714-723.
41. Thalheimer W, Cook S (2002). How to calculate effect sizes from published research articles: a simplified methodology. Available at: http://www. worklearning. com/. [Accessed 12 May 2011].
42. Wall GC,Wasiak A, Hicklin GA (2006). An initially unsuspected case of baclofen overdose. Am J Crit Care 15:611-613.
43. Waters A, Hill A, Waller G (2001). Internal and external antecedents of binge eating episodes in a group of women with bulimia nervosa. Int J Eat Disord 29:17-22.
44. White MA,Whisenhunt BL,Williamson DA, Greenway FL, Netemeyer RG (2002). Development and validation of the food-craving inventory. Obes Res 10: 107-114.
45. Wojnicki FHE, Roberts DCS, Corwin RLW(2006). Effects of baclofen on operant performance for food pellets and vegetable shortening after a history of binge-type behavior in non-food-deprived rats. Pharmacol Biochem Behav 84:197-206.
46. Wong KJ, Wojnicki FHW, Corwin RLW (2009). Baclofen, raclopride, and naltrexone differentially affect intake of fat/sucrose mixtures under limited access conditions. Pharmacol Biochem Behav 92:528-536.
47. Xi ZX, Stein EA (1999). Baclofen inhibits heroin self-administration behavior and mesolimbic dopamine release. J Pharmacol Exp Ther 290:1369-1374.
48. Zigmond AS, Snaith RP (1983). The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 67:361-370.